The shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) were last seen up 10.7% to trade at $8.36, after the U.S. Food and Drug Administration (FDA) reportedly accepted the company's license application for its advanced melanoma treatment. Plus, IOVA received a price-target hike from Stifel to $24 from $21.
The security is once again bouncing off support at the $7 region, and earlier came close to conquering last week's annual high of $9.36. The shares are also back above the 200-day moving average, after a brief slip below this trendline, as they look to snap their three-day losing streak. Year-to-date, IOVA is up 34%.
Short sellers are already hitting the exits, with short interest down 2.1% during the most recent reporting period. However, the 23.38 million shares sold short still account for 11.2% of the equity's available float, or over one week's worth of pent-up buying power. An unwinding of this pessimism could boost IOVA.
So far today, 6,444 calls and 1,614 puts have already crossed the tape, which is 11 times the intraday average volume. Most popular is the June 10 call, followed by the 7.50 put in that series.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
